ArticleFrontiers in cardiovascular medicine2025
Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI undergoing PCI.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of loading dose atorvastatin on postoperative cardiovascular events in elderly patients with acute myocardial infarction undergoing percutaneous coronary intervention.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myocardial infarction in the elderly often leads to significant left ventricular structural remodeling, which adversely affects prognosis. This study aims to evaluate the effects of intensive rosuvastatin therapy on markers of ventricular remodeling and cardiac function following percutaneous coronary intervention (PCI) in elderly patients with ST-segment elevation myocardial infarction (STEMI). Methods: This study enrolled 100 patients aged ≥60 years with STEMI who underwent emergency PCI. The patients were randomly assigned to either an intensive therapy group ( Results: After 8 weeks of treatment, the intensive group showed significantly reduced serum inflammatory levels compared to the control group, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and intercellular adhesion molecule-1 (ICAM-1) ( Conclusion: In elderly patients with STEMI, high-dose rosuvastatin demonstrates superior therapeutic efficacy compared to conventional-dose therapy in alleviating inflammatory responses, improving ventricular remodeling, and enhancing cardiac function. Clinical Trial Registration: [www.chictr.org.cn], identifier [ChiCTR2200066956].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.